Structural and functional characterization of a modified legionaminic acid involved in glycosylation of a bacterial lipopolysaccharide

Nathan D. McDonald  
*University of Delaware*

Kristen E. DeMeester  
*University of Delaware*

Amanda L. Lewis  
*Washington University School of Medicine in St. Louis*

Catherine Leimkuhler Grimes  
*University of Delaware*

E. Fidelma Boyd  
*University of Delaware*

Follow this and additional works at: [https://digitalcommons.wustl.edu/open_access_pubs](https://digitalcommons.wustl.edu/open_access_pubs)

Please let us know how this document benefits you.

**Recommended Citation**

[https://digitalcommons.wustl.edu/open_access_pubs/8434](https://digitalcommons.wustl.edu/open_access_pubs/8434)

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact vanam@wustl.edu.
Nonulosonic acids (NulOs) are a diverse family of α-keto acid carbohydrates present across all branches of life. Bacteria biosynthesize NulOs among which are several related prokaryotic-specific isomers and one of which, N-acetylenuraminic acid (sialic acid), is common among all vertebrates. Bacteria display various NulO carbohydrates on lipopolysaccharide (LPS), and the identities of these molecules tune host–pathogen recognition mechanisms. The opportunistic bacterial pathogen *Vibrio vulnificus* possesses the genes for NulO biosynthesis; however, the structures and functions of the *V. vulnificus* NulO glycan are unknown. Using genetic and chemical approaches, we show here that the major NulO produced by a clinical *V. vulnificus* strain CMCP6 is 5-N-acetyl-7-N-acetyl-d-alanyl-legionaminic acid (Leg5Ac7AcAla). The CMCP6 strain could catabolise modified legionaminic acid, whereas *V. vulnificus* strain YJ016 produced but did not catabolise a NulO without the N-acetyl-d-alanyl modification. In silico analysis suggested that Leg5Ac7AcAla biosynthesis follows a noncanonical pathway but appears to be present in several bacterial species. Leg5Ac7AcAla contributed to bacterial outer-membrane integrity, as mutant strains unable to produce or incorporate Leg5Ac7AcAla into the LPS have increased membrane permeability, sensitivity to bile salts and antimicrobial peptides, and defects in biofilm formation. Using the crustacean model, *Artemia franciscana*, we demonstrate that Leg5Ac7AcAla-deficient bacteria have decreased virulence potential compared with WT. Our data indicate that different *V. vulnificus* strains produce multiple NulOs and that the modified legionaminic acid Leg5Ac7AcAla plays a critical role in the physiology, survivability, and pathogenicity of *V. vulnificus* CMCP6.

Nonulosonic acids (NulOs), which include the sialic acids, are a family of nine carbon α-keto sugars that serve as critical recognition elements between cells. The most common sugar, N-acetylenuraminic acid (Neu5Ac) (otherwise known as sialic acid) (1), is found in most lineages of metazoans and performs a wide range of functions in eukaryotes such as cell to cell communication (Fig. 1). Although these carbohydrates are utilized by eukaryotes, bacteria can both biosynthesize and catabolise sialic acid (1–5). The ability to catabolise sialic acid is widespread among both commensal and pathogenic species (3, 6). Specifically, the catabolism of NulOs is an important phenotype for host–pathogen interactions (3, 6–9). Certain bacteria also utilise sialic acid to decorate their cell-surface structures such as the lipopolysaccharide (LPS) and/or capsule polysaccharide (CPS) (10–17). Sialic acids on the cell surface contribute to the evasion of the host immune response as a form of molecular mimicry (18–24).

Although sialic acid is found in eukaryotes and some prokaryotes, it is not the predominant NulO produced in bacteria. Nine carbon α-keto sugars bearing a strong resemblance to sialic acid such as derivatives from 5,7-diamino-3,5,7,9-tetradeoxy-non-2-ulosonic acids (Fig. 1, Fig. S1) have been characterized as prokaryote-specific NulOs. Traditionally, these prokaryote-specific NulOs are further categorized into one of four classes of carbohydrates based on their stereochemistry: pseudaminic, legionaminic (Leg), or two epimers of Leg, 4-epi-legionaminic acid and 8-epi-legionaminic acid (25–27). However, recent studies have described three new NulOs, specifically acinetaminic (Ace) and 8-epiacinetaminic acid found in the CPS of *Acinetobacter baumannii* and fusaminic acid (Fus) from the LPS of *Fusobacterium nucleatum* (Fig. S1) (28–30). The prokaryotic NulOs have been identified in various surface structures, including the LPS and CPS as well as N- and O-linked glycans on flagella and pili (31–37). Although significant work has investigated the role of sialic acid in molecular mimicry and host evasion, the chemical composition and
Modified legionaminic acid in bacterial lipopolysaccharides

Figure 1. Nonulosonic acids are a structurally diverse family of carbohydrates present on the surface of cells across all branches of life. These carbohydrates play a critical role in various cell communications and host–pathogen interactions. This work describes a prokaryote-specific nonulosonic acid (Leg5Ac7AcAla) in the lipopolysaccharide of the marine pathogen *V. vulnificus*, which is required for its survivability.

role of bacteria-specific NulOs in host–pathogen interactions remain under-explored. In addition to the seven isomers of the prokaryote-specific NulOs described, these carbohydrates can display various functionalized N- and O-substitutions such as acetylation. These diverse modifications may further contribute to multiple pathogen–host interaction mechanisms in vivo and in the environment (38). The wide array of structural variants and the newest discoveries Ace and Fus motivated our efforts to discover unique functional groups and novel isomers within the model organism *Vibrio vulnificus*.

Previous work from our group confirmed that strains of *V. vulnificus*, a marine bacterium and human opportunistic pathogen, produced NulOs; however, the genomic region responsible for the NulO biosynthesis was highly variable within the species (Fig. 2A) (39). One study fully elucidated the inner core of the LPS from the *V. vulnificus* strain ATCC 27562, which was found to have a pseudoamine as a carbohydrate component (40). Biochemical analysis of *V. vulnificus* strains with divergent NulO biosynthetic loci revealed that highly variable levels of NulO were produced depending on the genotype; however, no detailed NulO structural information was elucidated (39). Two *V. vulnificus* strains in particular, CMCP6 and YJ016, were studied in more detail. These two strains are nearly identical; however, the NulO biosynthetic region is unrelated (Fig. 2A). *V. vulnificus* strains with the CMCP6-like NulO genes produce ∼100-fold more NulO than strains with the YJ016-like genes (41).

Efforts from our laboratory to connect the genetic NulO fingerprint with *V. vulnificus* pathogenicity revealed that NulO-deficient mutants have significantly increased sensitivity to the bacterial antimicrobial peptide polymyxin B (PmB), defects in swimming and biofilm formation, and are attenuated in a mouse bloodstream model of infection (41). The extent of bacterial bloodstream survival and dissemination was proportional to the amount of NulO expressed by the WT strain (NulO expression: CMCP6 >> YJ016) (41). In addition, *V. vulnificus*, mutants in the NulO biosynthetic pathway were defective in virulence (42).

Given the correlation between NulO display and bacterial pathogenesis, we chemically characterized the carbohydrate biosynthesized in strain CMCP6, which produces higher levels of NulO (39, 41). We found that a modified legionaminic acid is produced in strain CMCP6, with an N-acetyl-D-alanyl group at C-7 (Leg5Ac7AcAla, Fig. 1). Through gene deletion analysis, we demonstrate that the modified Leg, 5-N-acetyl-7-D-alanyl-legionaminic acid (Leg5Ac7Ala), lacking an acetyl group, is catabolized via the canonical sialic acid pathway. Further analysis of deletion mutants demonstrate that biosynthesis of the acetylated D-alanine carbohydrate is essential for outer membrane integrity, stress survival, and virulence in the brine shrimp model *Artemia franciscana*.

Results

*V. vulnificus* CMCP6 biosynthesizes a modified legionaminic acid

To begin to determine the structure of *V. vulnificus* NulOs embedded in the sequence and genomic organization of the biosynthesis pathways, we first investigated whether the NulO biosynthesis genomic loci were homologous to previously characterized pathways. The predicted biosynthesis operon of strain CMCP6 was similar in gene arrangement and amino acid composition with the biosynthetic region from *Escherichia coli* O161 (Fig. 2B). Specifically, the Nab1, Nab2, and Nab3 proteins of CMCP6 shared 54, 81, and 73% amino acid identity with Lea7, Lea4, and Lea5 of *E. coli* O161. The LPS from *E. coli* O161 contains a 5-N-acetyl-7-D-alanyl-legionaminic acid (Leg5Ac7Ala) (43). The Leg5Ac7Ala is modified with a D-alanine at C-7 compared with the typical acetamido group in legionaminic acid (Fig. 2C). Interestingly, the operon of CMCP6 contained a putative N-acetyltransferase (i.e. nab5), which was absent from the *E. coli* operon (Fig. 2B). We hypothesized that this N-acetyltransferase would acetylate the free amine of the D-alanine, resulting in a NulO with a 7-N-acetyl-D-alanyl modification at C-7 (Fig. 2C). To determine whether CMCP6 does in fact produce this modified Leg, the NulOs were released from CMCP6 via mild acid hydrolysis in 2 N acetic acid, derivatized with the fluorescent molecule 1,2-diamino-4,5-methylene dioxybenzene (DMB), and separated via HPLC as described previously (Fig. 3A) (41, 44). The major NulO peak eluted at ∼17 min (Fig. 3B). The derivatized NulO was collected and analyzed by electrospray ionization MS (ESI-MS). The [M + H]+ of 522.17 m/z as well as the [M + Na]+ of 544.21 m/z from the NulO peak were consistent with the predicted modification that corresponds to a derivatized NulO modified with acetylated alanine (Leg5Ac7AcAla) (Fig. 3C).

To characterize in more detail the native NulO structure, the LPS of WT CMCP6 was purified via the hot water/phenol...
method (45), and the NuLO was released from purified LPS of CMCP6 in 6% acetic acid for 4 h at 100 °C. The hydrolysate was separated by size-exclusion chromatography. The fractions containing NuLOs, as indicated by staining with p-anisaldehyde via thin-layer LC (TLC), were collected and analyzed via high-resolution LC–MS (HR LCMS) to confirm the presence and identity of the native carbohydrate (Fig. 4). The expected ionization pattern for the native NuLO (Leg5Ac7AcAla) was confirmed via HR LCMS to include the dehydrated mass [M – 18]+ of 388 m/z, [M + H]+ of 406 m/z, and [M + Na]+ of 428 m/z (Fig. 4).

Detailed structural 1H NMR and 13C NMR analyses were conducted on the native NuLO (Leg5Ac7AcAla) fractions. 460 mg of LPS was purified from 45 liters of culture, and the LPS was hydrolyzed in acetic acid to release the NuLOs, which were further purified for NMR characterization in D2O (Fig. S2, A–D). The NMR analysis revealed the presence of the corresponding CH3 of the alanine functionality upfield (~1.5 ppm) from hydrogens attached to α-carbon downfield (~3.9 ppm) as indicated via 2D 1H NMR analysis (Fig. S2, C and D). These signature chemical shifts confirmed that the NuLO produced by V. vulnificus CMCP6 contained an alanyl functionality. In tandem with the MS data and genomic analysis, the NuLO structure was determined to be 5-N-acetyl-7-D-alanyl-legionaminic acid (Leg5Ac7AcAla) (Fig. 2C).

Catabolism of 5-N-acetyl-7-α-alanyl-legionaminic acid in V. vulnificus CMCP6

Our previous studies demonstrated that there are variable amounts of NuLO produced depending on the genotype of V. vulnificus strains. In particular, strain CMCP6 produces 100-fold more NuLO than YJ016 under the same culture conditions (Fig. 5, A and B) (41). When characterizing the biosynthetic loci of these strains, the Δnab1 deletion resulted in the opposite phenotype in which YJ016 produced more NuLO than CMCP6. The Nab1 enzyme is a cytidine monophosphate (CMP)–NulO synthetase and catalyzes the transfer of CMP from CTP to activate the NuLO for use by a downstream glycosyltransferase, ultimately linking the sugar to LPS (46). No detectable NuLO was observed in the HPLC analysis of DMB-derivatized total cellular fractions of the CMCP6 Δnab1 mutant (Fig. 5C), suggesting that the Leg5Ac7AcAla is catabolized by this strain. Conversely, in the YJ016 Δnab1 we observe accumulation of a NuLO eluting at ~14 min, which suggests that this carbohy-
Figure 3. Confirmation of predicted structure in CMCP6 by HPLC and mass spectrometry. A, derivatization reaction of acid released NulOs with the fluorescent molecule DMB. B, nonulosonic acids were derivatized with DMB and separated by reverse-phase HPLC, and absorbance was measured at 373 nm. C, separated DMB–NulOs were isolated and subjected to ESI-MS analysis. The major ion corresponds to the expected size [M + H]+ of 522 m/z and [M + Na]+ of 544 m/z consistent with the predicted structure.
drate is not catabolized (Fig. 5D). Mass spectrometry analysis of the derivatized NulO revealed the accumulation of an unfunctionalized NulO such as legionaminic or pseudaminic acid (Fig. S3, A and B).

Because Leg5Ac7AcAla does not appear to accumulate in the CMCP6 Δnab1 strain, the carbohydrate might be catabolized further within the cell. Previous work from our group has demonstrated the genes required for sialic acid transport and catabolism are lineage-specific within V. vulnificus and that CMCP6 can utilize sialic acid as a sole carbon and energy source (Fig. S4A) (47). Therefore, a double deletion mutant of ΔnanA/Δnab1 in which the first sialic acid catabolic enzyme, N-acetylneuramininate lyase (NanA), is deleted along with Δnab1 would be predicted to cause the accumulation of Leg5Ac7AcAla within the cell (Fig. 2C and Fig. S4B). The single ΔnanA deletion mutant produced Leg5Ac7AcAla in similar amounts to WT CMCP6, and this mutant also accumulates sialic acid from the medium inside the cell (Fig. S4C). However, the DMB

Figure 4. High-resolution MS analysis of purified nonulosonic acid from V. vulnificus CMCP6. The modified nonulosonic acid was released from purified LPS via mild acid hydrolysis in 6% acetic acid, separated by size-exclusion chromatography, and then analyzed by HR MS of separated modified-NulO from CMCP6 LPS.

Figure 5. Analysis of nab1 deletion mutants from V. vulnificus CMCP and YJ016. Total cellular fractions were derivatized with DMB, and the derivatized NulOs were separated by HPLC monitoring absorbance at 373 from either WT CMCP6 (A), WT YJ016 (B), CMCP6 Δnab1 (C), or YJ016 Δnab1 (D).
**Modified legionaminic acid in bacterial lipopolysaccharides**

**Proposed biosynthesis pathway for Leg5Ac7AcAla**

Based on the data presented and the previously reported biosynthetic pathways (43, 46), we propose an eight-step pathway for the production of the Leg5Ac7AcAla in *V. vulnificus* CMCP6 (Fig. 7, A and B). In this model, the biosynthesis of Leg5Ac7AcAla proceeds with several key differences from what has been described for Leg (46). The addition of the d-alanine is predicted to be catalyzed by Nab4 (VV1_0809), which is annotated as an N-acetyltransferase. Nab4 contains a partial N-acetyltransferase superfamily domain, which includes a broad class of enzymes catalyzing various acylation reactions, including amino acid modifications. We predict that Nab4 is the alanyltransferase due to the shared homology with Lea3 from *E. coli* O161, which biosynthesizes the d-alanyl-legionaminic acid (Fig. 2C).

In addition to the d-alanine modification, the second unique step in this biosynthetic pathway is the acetylation of this alanine residue by the enzyme encoded by *nab5* (VV1_0805). Nab5 is a predicted N-acetyltransferase with a complete acetyltransfer_3 domain, which specifically catalyzes N-acetylation reactions. Our analysis of the ∆nanA/∆nab1 deletion mutant demonstrated that Leg5Ac7Ala accumulates in the cell and is lacking the second acetyl group when compared with WT CMCP6 (Fig. 6). This result would suggest that the acetylation reaction occurs after the addition of the nucleotide CMP by Nab1, which was always considered the last step in canonical NuLO biosynthesis pathways (Fig. 7B).

**Membrane integrity of nonulosonic acid mutants**

NuLO mutants have increased sensitivity to antimicrobial peptides, specifically PmB (Fig. S5) (41, 48). To determine whether PmB induces outer membrane permeability in the NuLO mutant, a lysozyme permeability assay was utilized. Under normal growth conditions, Gram-negative bacteria exhibit resistance to lysozyme, an enzyme that cleaves the carbohydrate units of bacterial peptidoglycan (PG), because the LPS limits access to the PG layer (49). If the outer membrane becomes permeabilized, the lysozyme can gain access to the PG and cause cell lysis. Both the WT and ∆nab2 deletion mutant, producing no Leg5Ac7AcAla, were subjected to sub-lethal concentrations of both PmB and lysozyme in combination, and the optical density was measured for cell lysis. Under these conditions, the ∆nab2 mutant cells lysed significantly more than WT (Fig. 8A). This result indicates that the PmB is acting synergistically by permeabilizing the outer membrane of the ∆nab2 mutant, allowing lysozyme to cause cell lysis, whereas the WT remains unaffected. Previously, we demonstrated that complementation with a functional *nab2* gene in ∆nab2 restores Leg5Ac7AcAla biosynthesis, although not back to WT levels (41). We evaluated the ∆nab2 complement strain for sensitivity to PmB-induced membrane permeability, and we found the defect was rescued compared with the ∆nab2 mutant, albeit not to WT levels, likely due to insufficient Leg5Ac7AcAla production (Fig. 8A). To further assess the membrane integrity under physiologically relevant conditions, we performed survival assays in 15% sodium cholate, a bile salt with a detergent-like mechanism of action. CFUs were determined 0, 30, and 60 min.

---

**Figure 6. Catabolism of Leg5Ac7Ala in *V. vulnificus* CMCP6.** Total cellular fractions were derivatized with DMB and separated by HPLC, and absorbance was measured for CMCP6 ∆nanA/∆nab1 (A). B, derivatized NuLOs were collected and analyzed by ESI-MS revealing a mass of [M + H]⁺ of 479 corresponding to the loss of an acetyl group compared with WT. C, schematic of the accumulation of Leg5Ac7Ala in the ∆nanA/∆nab1 double mutant of *V. vulnificus* CMCP6.

derivatization of the total cellular fractions of the CMCP6 ∆nanA/∆nab1 followed by HPLC revealed the accumulation of a different NuLO molecule, as the HPLC retention time and signal intensity were different from what was shown for Leg5Ac7AcAla (Figs. 2C and 6A). Mass spectrometry analysis of this molecule accumulating within the ∆nanA/∆nab1 mutant revealed a mass of [M + H]⁺ of 480.2 m/z, 42 less than WT Leg5Ac7AcAla corresponding to the loss of an acetyl group from the sugar (Fig. 6B). This result shows that 5-N-acetyl-7-d-alanyl-legionaminic acid (Leg5Ac7Ala) can be catabolized via NanA when Nab1 is inactivated (Fig. 6C).
following exposure. The Δnab2 mutant exhibited an approximate log decrease in CFUs immediately following exposure to bile salts, and this defect continued throughout the experiment (Fig. 8B). Together, these results indicate that the biosynthesis of Leg5Ac7AcAla and that the LPS modification by Leg5Ac7AcAla are important for the outer membrane integrity of V. vulnificus particularly in the presence of antimicrobial peptides. The Δnab2 complement strain was evaluated for bile sensitivity and shown to rescue the phenotype; however, the strain was more resistant to sodium choleate compared with WT CMCP6 (Fig. 8B). This result suggests that the decreased levels of Leg5Ac7AcAla produced in the complement may be more advantageous for choleate resistance in V. vulnificus CMCP6.

Previously, we demonstrated that the Δnab2 mutant of CMCP6 was attenuated in a mouse bloodstream model of infection (41). Because of the effects to membrane integrity and sensitivity in the presence of PmB, the Δnab2 mutant could be defective in human serum, which contains the antimicrobial complement cascade but lacks any immune cells. However, survival assays in total human serum were conducted, and CFUs were measured over the course of 2 h post-exposure, and we found that the Δnab2 mutant had no survival defect (Fig. S6A). A translucent variant strain CMCP6/T lacking a capsule, previously shown to be essential for serum resistance (50), was cleared after serum exposure for 30 min (Fig. S6A). All strains were able to survive in heat-inactivated serum (Fig. S6B).

**Leg5Ac7Ala contributes to biofilm formation**

Previous work demonstrated that the Δnab2 mutant of V. vulnificus CMCP6 was defective in biofilm formation, and NulO biosynthesis has been implicated in biofilm formation in several other bacteria (36, 41, 51–53). It was speculated that the presence of NulO may contribute to the V. vulnificus biofilm formation mechanism. A preliminary investigation into the role of NulOs in biofilm was conducted utilizing crystal violet staining. After 24 h, the Δnab1 mutant exhibited a decrease in biofilm formation compared with WT CMCP6, which was restored albeit not back to WT levels following nab1 complementation (Fig. 8C and Fig. S7). However, this defect was abolished in the Δnana/Δnab1 double deletion mutant, which accumulates Leg5Ac7Ala within the cell (Fig. 8C). This result suggests that the accumulation of Leg5Ac7Ala overrides the original defect in biofilm formation, despite the inability to activate the carbohydrate with a CMP moiety (Fig. 8C, Fig. 2C). A more detailed analysis is required to fully understand the composition and regulation of biofilm formation in these NulO mutants of V. vulnificus.

**Leg5Ac7AcAla mutants are attenuated in virulence toward A. franciscana**

Because of the conservation of nonulosonic acid biosynthesis pathways within V. vulnificus, we speculated that these sugars would be important for survival and/or pathogenesis in the marine environment. A. franciscana is a model crustacean and has previously been used to assess V. vulnificus virulence factors (54–56). Here, the ability of WT CMCP6 and the Δnab1 and Δnab2 deletion mutants to kill A. franciscana nauplii was examined. Artemia cysts were hatched in artificial seawater, and subsequently, the nauplii were exposed to 1 × 10⁶ CFUs of either WT, nab mutants, or autoclaved CMCP6 control and were monitored as alive or dead 24 and 48 h following exposure. At the end of 2 days, there was a 21.7% survival rate of nauplii that were infected with WT CMCP6. Comparatively, there
was 59 and 57.7% survival for the Δnab1 and Δnab2 deletion mutants, respectively (Fig. 8D). The WT CMCP6 was significantly more virulent toward the nauplii than the Leg5Ac7 AcAla null strains. However, these strains are more virulent than the heat-killed bacteria control in which 85% of the nauplii survived (Fig. 8D). Complementation of the Δnab1 and Δnab2 mutants with functional copies of nab1 or nab2 did not completely restore virulence potential as the nauplii exhibited a survival rate of 51.7% following exposure to these strains (Fig. 8D). The inability to complement back to WT is likely due to the insufficient Leg5Ac7AcAla production across the 48-h incubation time.

Discussion

Nonulosonic acid chemistry and structural diversity are expanding fields, with new isomers and modifications still being discovered and characterized. These unique carbohydrates, key building blocks of LPS, are implicated in various pathologies of virulent bacteria as well as their overall survivability. Here, we characterized the NulOs of the opportunistic human pathogen *V. vulnificus* strains. The strains were grown statically for 24 h in Marine broth at room temperature. Biofilms were stained with 0.1% crystal violet and photographed, and the A was measured following resuspension in DMSO. Individual points represent average biological replicates from six technical replicates. Lines indicate mean and S.D. D, *A. franciscana* model of infection. Artemia nauplii were hatched in artificial seawater and exposed to 1 × 10⁶ CFU of either WT CMCP6, Δnab1, Δnab2, the nab1 complement, the nab2 complement, or heat-killed (HK) control CMCP6. Survival of the nauplii was determined at 24 and 48 h following exposure. Individual points represent independent experiments consisting of three technical replicates. Bar graph indicates mean, and error bars represent S.D. Welch’s ANOVA with Games-Howell post-hoc analyses. * indicates p < 0.05.
clinical isolates of V. vulnificus suggesting that this NulO is prominent within this species (39). In addition, Leg5Ac7AcAla is not limited to V. vulnificus, because bioinformatics analysis identified homologous biosynthetic pathways in many other bacterial species (Fig. 9). Included in this list are several fish pathogens (such as Aliivibrio wodanis and Aeromonas popofii) as well as the significant human pathogen Vibrio paraheamolyticus. Indeed, Leg5Ac7AcAla was identified in the LPS of an O-untypable strain of V. paraheamolyticus (57).

Deletion of key biosynthetic enzyme genes suggested that acetylation of the alanyl group occurs after the addition of the CMP sugar carrier. The activation with CMP is typically considered the final step of the NulO biosynthesis prior to incorporation into the downstream structures. We propose that V. vulnificus utilizes a post-CMP–NulO modification strategy in which the free amine of the D-alanine is acetylated. Interestingly, previous work has proposed other modifications of NulOs that occur on the CMP-NulO in Campylobacter jejuni (58).

The genomic regions encoding the NulO biosynthetic pathway in V. vulnificus strains CMCP6 and YJ016 are highly variable in gene content and arrangement with very little shared homology. The lack of nab4 and nab5 homologs in YJ016 indicates that the N-acetyl-\(\alpha\)-alanyl NulO modification does not occur in this strain. The biochemical analysis of the NulO of YJ016 via HPLC and ESI-MS indicates that this carbohydrate is of the di-\(N\)-acetylated variety characteristic of bacterial NulOs without any further modifications. Furthermore, this carbohydrate is possibly a stereoisomer other than Leg, due to the inability of this NulO to be catabolized by the sialic acid catabolism pathway and NanA.

The Leg5Ac7Ala NulO can be catabolized via the sialic acid degradation pathway in V. vulnificus CMCP6 (Fig. 6). This finding is of particular interest as the ability to utilize sialic acid as a nutrient has been implicated in host colonization in various pathogens (6, 7, 9). Previously, we demonstrated that sialic acid catabolism enhances colonization by Vibrio cholerae (6, 7). We showed that sialic acid catabolic pathways are largely associated with mucosa-associated commensals and pathogens (3, 6, 7). Both Leg5Ac7AcAla and sialic acid have the same stereochemistry in the carbohydrate core. Therefore, the sialic acid catalytic enzymes may exhibit substrate promiscuity and act on Leg allowing catabolism of these prokaryotic NulOs as we have demonstrated here with NanA of V. vulnificus. Further research is required to determine whether prokaryote-specific NulOs such as Leg can be scavenged from diverse microbial populations and utilized as an exogenous energy source contributing to niche expansion.

The NulO biosynthetic mutants have increased sensitivity to the antimicrobial peptide PmB, which is also able to permeabilize the membrane of the mutants compared with WT. We predicted that the defect in membrane integrity in the presence of PmB could explain our previous work, which showed that these mutants are readily cleared by the immune system in vivo (41). However, we found here that these same mutants are not sensitive to human serum in vitro, suggesting there is something present in vivo, beyond the antimicrobial activity of the complement cascade, that is responsible for the clearing of the NulO-deficient strains. This result is further supported by a recent study examining V. vulnificus YJ016 growth in serum that found the NulO biosynthetic genes were not involved in serum survival (59).
The conserved ability to produce NulOs within V. vulnificus implies that these carbohydrates are essential for survival in the aquatic reservoir. Naturally, V. vulnificus can be commensal with phytoplankton, fish, and various crustaceans where in some cases the bacteria can be pathogenic. We show that NulO biosynthesis is required for virulence in the model crustacean organism A. franciscana. One explanation for the decreased virulence of the Leg5Ac7AcAla null strains is that there may be antimicrobial peptides produced by the A. franciscana brine shrimp which the NulO mutants are sensitive to resulting in their attenuation. Additionally, the mutated carbohydrates of LPS along with the fact that these strains are not fully motile may affect binding to the chitinous surface of the shrimp resulting in decreased virulence.

The NulOs described here and their carbohydrate modifications are highly prokaryote-specific. Two genes, nab4 and nab5, which putatively catalyze the addition of a D-alanine and acetylation of D-alanine, respectively, are unique in that D-alanine is predominantly limited to bacteria. The distinctive functions of NulO-modifying enzymes such as Nab4 and Nab5 as well as the significant role of NulOs in numerous pathogens makes the NulO biosynthetic proteins promising targets for antimicrobial therapies. Because of their prominence on surface structures, the NulO modifications such as the 7-N-acetyl-D-alanyl group described here can be targeted for vaccine development.

We have demonstrated that genetic diversity at the nonulosonic acid biosynthesis loci within V. vulnificus results in variable NulO structures ultimately altering the LPS. We chemically characterized a functionalized NulO, Leg5Ac7AcAla, in the pathogenic strain V. vulnificus CMCP6 and showed that modified legionaminic acid can be catabolized by the cell. Physiological characterizations of NulO mutants demonstrate how these carbohydrates contribute to biofilm formation, membrane integrity, and virulence toward crustaceans. These findings contribute to the ongoing efforts toward deconvoluting the production, structural elements, and processing of NulOs displayed by many species of bacteria. This information is critical for understanding the role of NulOs in host–pathogen recognition, their potential as virulence factors, and as targets for novel antimicrobial therapies.

**Experimental procedures**

**Strains and culture conditions**

This study utilized the V. vulnificus clinical isolates CMCP6 and YJ016. Strains and plasmids used are listed in Table 1. All strains were grown aerobically at 37 °C in Lysogeny Broth (LB) (ThermoFisher Scientific, Fair Lawn, NJ) containing 2% NaCl. Strains were grown overnight from a single colony. Where indicated, overnight cultures were subcultured in fresh LB 2% to obtain logarithmic growth. All strains used are resistant to streptomycin, and where indicated, antibiotics were utilized at the following concentrations: streptomycin 200 μg/ml, chloramphenicol 25 μg/ml.

### Allelic exchange mutagenesis in V. vulnificus

V. vulnificus CMCP6 and YJ016 genome sequences were used for primer design, and oligonucleotides were purchased from Integrated DNA Technologies (Coralville, IA) and are listed in Table 2. An in-frame deletion of CMCP6 nab2 was created previously (41). In-frame nonpolar gene deletions of nab1 in both strains CMCP6 and YJ016 were constructed via splicing by overlap extension PCR and homologous recombination as described previously (60). Primers were designed to amplify the regions flanking either CMCP6 VV1_0803 (nab1) or YJ016 VV0316 (nab1). A double deletion strain of ΔnanA/Δnab1 in CMCP6 was generated starting with a ΔnanA background in which the nab1 gene was next deleted. Gene fragments were spliced together by PCR and complementary ends, cloned into the suicide vector pDS132, and transformed into the donor strain E. coli J2155. The donor strains were conjugated overnight with the recipient V. vulnificus strain. Strains that had integrated the deletion vector into the genome via homologous recombination were selected on LB 2% plates supplemented with chloramphenicol. Colonies were subsequently grown overnight in LB 2% without selection and plated on LB
2% plates supplemented with 10% sucrose to select for the second round of homologous recombination. The double colonies were confirmed to be deletion mutants via PCR. Complement strains were generated similarly using primers listed in Table 2 and cloned into the expression vector pBBR1MCS. Complement strains were induced with 0.05 mM isopropyl-β-D-galactopyranoside.

**DMB derivatization of V. vulnificus NulOs**

*V. vulnificus* cultures were grown overnight in LB 2%. Cells were pelleted and washed in PBS followed by subsequent washes in ethanol and acetone to dry the bacterial pellets.

**TLC of separated NulOs**

Thin layer chromatography (TLC) in which glass plates coated with silica gel (250 μm, Silica Gel HL, Sorbent Technologies) were used and visualized with shortwave 254 nm UV light or developed upon heating with p-anisaldehyde.

**HPLC and MS analysis of V. vulnificus NulOs**

Analytical and semi-preparative HPLC was performed on an Agilent Series 1100 using a Phenomenex® Luna 5-μm C18 column (250 × 10.00 nm). Low-resolution mass spectra were obtained on a Shimadzu LCMS 2020 or a Waters SQD2 instrument using ESI. High-resolution mass spectra (HR-MS) were obtained on a ThermoFisher Scientific Q-Exactive Orbitrap at the Mass Spectroscopy Facility at the Department of Chemistry, University of Delaware.

**Nuclear magnetic resonance of purified NulOs**

All NMR spectra were recorded on Bruker AV 400 MHz and AV III 600 MHz spectrometers. Proton chemical shifts were recorded in parts per million (ppm) on the δ scale, downfield from tetramethylsilane and referenced from an internal standard of residual protium in the NMR solvents (HDO: δ 4.87). Data for 13C NMR were recorded in ppm downfield from tetramethylsilane. NMR data were reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and br = broad), coupling constant in Hz, integration, and assignment based on two-dimensional COSY, HSQC, and HMBC experiments. NMR processing was done using MestReNova 2005–2017 Research SL Software. Chemical shifts of Leg5Ac7AcA were as follows: 1H NMR (600 MHz, deuterium oxide) δ 5.09 (s, 1H), 5.00 (d, J = 6.2 Hz, 1H), 4.94–4.84 (m, 3H), 4.52 (d, J = 10.8 Hz, 1H), 4.40–4.34 (m, 2H), 4.34–4.26 (m, 3H), 4.19 (ddt, J = 19.1, 12.5, 6.7 Hz, 5H), 4.11 (d, J = 6.2 Hz, 2H), 4.09–3.93 (m, 9H), 3.86 (ddq, J = 15.8, 10.0, 5.9 Hz, 5H), 3.82–3.66 (m, 7H), 3.65–3.55 (m, 3H), 3.50 (dd, J = 11.8, 6.5 Hz, 1H), 3.23 (dd, J = 13.8, 5.8 Hz, 1H), 3.14 (t, J = 7.8 Hz, 1H), 3.06 (t, J = 7.8 Hz, 1H), 2.11–2.00 (m, 14H), 1.98 (d, J = 25.1 Hz, 1H), 1.94 (d, J = 5.4 Hz, 7H), J = 25.1 Hz, 1H), 1.12 (s, 1H), 1.11 (d, J = 5.8 Hz, 4H). 13C NMR (101 MHz, D2O) δ 174.92, 174.80, 173.95, 173.79, 173.64, 173.17, 98.94, 98.43, 94.10, 78.06, 75.62, 72.85, 72.62, 71.93, 70.69, 70.45, 70.30, 68.07, 67.02, 66.16, 65.76, 64.54, 63.68, 62.33, 53.52, 53.42, 52.27, 50.10, 49.80, 48.62, 48.07, 45.80, 44.55, 36.41, 36.23, 23.65, 21.99, 21.89, 21.8, 21.65, 21.31, 19.14, 16.86, 16.48, 15.18.

**Purification of V. vulnificus lipopolysaccharide and isolation of Nulo**

*V. vulnificus* cultures were grown overnight in LB 2%. Cells were pelleted and washed in PBS followed by subsequent washes in ethanol and acetone to dry the bacterial pellets.

**Table 2**

<table>
<thead>
<tr>
<th>Primers</th>
<th>Sequence 5′–3′</th>
<th>Product size</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SOEVV1_0803A</strong></td>
<td>TCTAGAAGCGCTGCAGATGAGATTTACCTCA</td>
<td>241</td>
</tr>
<tr>
<td><strong>SOEVV1_0803B</strong></td>
<td>AACGCGCAGCTCTGGCCGCTCCCTCTCTGCT</td>
<td>227</td>
</tr>
<tr>
<td><strong>SOEVV1_0803C</strong></td>
<td>TGGTACGCGAGCGGTGACTACACAGTTTATTACCTCA</td>
<td>251</td>
</tr>
<tr>
<td><strong>SOEVV1_0803D</strong></td>
<td>TCTAGACGGCAACAAGAATAGTTTTAGCTGACTGACTGCT</td>
<td>1068</td>
</tr>
<tr>
<td><strong>SOEVV1_0803FF</strong></td>
<td>GGATCGCGAGCGGTGACTACACAGTTTATTACCTCA</td>
<td>224</td>
</tr>
<tr>
<td><strong>SOEVV1_0803FR</strong></td>
<td>GTGTACGCGAGCGGTGACTACACAGTTTATTACCTCA</td>
<td>240</td>
</tr>
<tr>
<td><strong>SOEVV2_0730A</strong></td>
<td>TCTAGAATATGCGCAGAATGAGATTTATTTATTTCT</td>
<td>247</td>
</tr>
<tr>
<td><strong>SOEVV2_0730B</strong></td>
<td>AACGCGCAGCTCTGGCCGCTCCCTCTCTCT</td>
<td>996</td>
</tr>
<tr>
<td><strong>SOEVV2_0730C</strong></td>
<td>TGGTACGCGAGCGGTGACTACACAGTTTATTACCTCA</td>
<td>744</td>
</tr>
<tr>
<td><strong>SOEVV2_0730D</strong></td>
<td>GGATCGCGAGCGGTGACTACACAGTTTATTACCTCA</td>
<td>1079</td>
</tr>
</tbody>
</table>
Modified legionaminic acid in bacterial lipopolysaccharides

Lipopolysaccharide was isolated from dried bacterial pellets using the hot water phenol method as described previously (45). Pellets were resuspended in equal volumes of water and 90% phenol at 70 °C with stirring for 30 min. All phases were dia lyzed to remove residual phenol. Proteins and nucleic acid were precipitated in 50% trichloroacetic acid (TCA) for 1 h at 4 °C. The precipitate was removed by centrifugation, and the LPS-containing fraction was lyophilized. Nonulosonic acids were removed by mild acid hydrolysis in 6% acetic acid for 3 h at 100 °C until a precipitate formed that was removed via centrifugation. The acid-hydrolyzed fraction was further separated via size-exclusion chromatography on Sephadex G-25. NulO containing fractions were combined and used for NMR analysis.

Bacterial survival assays in sodium cholate and human serum

To assess the fitness of NulO mutants, survival assays were conducted as described previously (61). V. vulnificus strains were cultured for 2 h to mid-exponential phase in LB 2%. Cells were pelleted and washed with PBS at which time CFUs were determined prior to exposure to the stress. For bile survival assays, bacteria were pelleted and suspended in an equivalent volume of 15% sodium cholate in LB and incubated at 37 °C for 1 h. CFUs were enumerated at 0, 30, and 60 min post-exposure. Experiments were completed in triplicate with at least two biological replicates. For serum survival assays, strains were grown overnight in 2% LB. A 1:40 inoculum of the overnight cultures was used to inoculate Marine broth in 96-well polystyrene plates (Corning Inc., CLS2593). Cultures were incubated statically at room temperature for 24 h allowing the biofilms to form. Following incubation, cultures were removed, and loosely adherent cells were washed twice with 200 µl of PBS. Biofilms were stained with 0.1% crystal violet for 30 min. The stain was removed, and biofilms were again washed twice with 200 µl of PBS. The stained biofilms were photographed and subsequently resuspended in dimethyl sulfoxide (DMSO) to solubilize the biofilm. The optical density (A950) was measured for 1:10 diluted biofilms. Biofilm determinations were performed with six replicate wells and three biological replicates.

Statistical analysis

Biological and technical replicates are indicated under “Experimental procedures” and figure legends. The data were analyzed by Welch’s ANOVA followed by a Games-Howell post hoc test. Data are presented as mean values ± S.D. A p < 0.05 was considered significant.


Acknowledgments—We thank Dr. Yiben Wang for technical help and Dr. Yuriy Knirel for advice on NulO isolation. We thank Dr. Papa Nii Asare-Okai (Director of the MS Facility) and Dr. Steve Bai (Department of Chemistry and Biochemistry, University of Delaware) for assistance in MS and NMR. For instrumentation support, the Delaware COBRE and INBRE Programs supported this project with National Institutes of Health Grants 5 P30 GM110758-02, P20GM104316-01A1, and P20 GM103446 from NIGMS.

References

Modified legionaminic acid in bacterial lipopolysaccharides

pathway characterization and first insight into biological implications. Glycobiology 27, 342–357 CrossRef Medline


Structural and functional characterization of a modified legionaminic acid involved in glycosylation of a bacterial lipopolysaccharide
Nathan D. McDonald, Kristen E. DeMeester, Amanda L. Lewis, Catherine Leimkuhler Grimes and E. Fidelma Boyd

doi: 10.1074/jbc.RA118.004966 originally published online October 12, 2018

Access the most updated version of this article at doi: 10.1074/jbc.RA118.004966

Alerts:
• When this article is cited
• When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 65 references, 27 of which can be accessed free at http://www.jbc.org/content/293/49/19113.full.html#ref-list-1